ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.54
-0.12 (-1.57%)
At close: 4:00PM EDT

7.54 0.00 (0.00%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close7.66
Open7.70
Bid6.49 x 3200
Ask8.01 x 800
Day's Range7.35 - 7.82
52 Week Range6.96 - 31.10
Volume749,718
Avg. Volume841,870
Market Cap362.898M
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.56
Trade prices are not sourced from all markets
  • Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
    Zacks7 hours ago

    Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH

    Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.

  • Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
    Zacks13 hours ago

    Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

    Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

  • Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher
    Zacks14 hours ago

    Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher

    Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

  • Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
    Zacks2 days ago

    Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

    Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.

  • Protalix (PLX) Completes Enrollment in Fabry Disease Study
    Zacks2 days ago

    Protalix (PLX) Completes Enrollment in Fabry Disease Study

    Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.

  • Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session
    Zacks2 days ago

    Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session

    Five Prime Therapeutics (FPRX) shares rose more than 9% in the last trading session, amid huge volumes.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for ACOR with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ACOR. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ACOR had net inflows of $2.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
    Zacks3 days ago

    Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy

    Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.

  • Dr. Reddy's Inks Deal to Sell Neurology Branded Products
    Zacks6 days ago

    Dr. Reddy's Inks Deal to Sell Neurology Branded Products

    Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

  • Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
    Zacks7 days ago

    Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

    Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.

  • NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
    Zacks7 days ago

    NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

    The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

  • Acorda Therapeutics Enters Oversold Territory
    Zacks7 days ago

    Acorda Therapeutics Enters Oversold Territory

    Acorda Therapeutics, Inc. (ACOR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
    Zacks8 days ago

    Denali's Hunter Syndrome Candidate Gets Orphan Drug Status

    The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.

  • Athenex Rallies on Positive Early Data on Psoriasis Candidate
    Zacks10 days ago

    Athenex Rallies on Positive Early Data on Psoriasis Candidate

    Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.

  • BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
    Zacks14 days ago

    BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

    BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

  • Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
    Zacks14 days ago

    Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

    The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

  • Myriad Genetics Announces Study Results Of myRisk Cancer Test
    Zacks15 days ago

    Myriad Genetics Announces Study Results Of myRisk Cancer Test

    The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

  • Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
    Zacks16 days ago

    Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR

    Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.

  • Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
    Zacks16 days ago

    Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

    Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

  • Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
    Zacks16 days ago

    Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

    Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.

  • Business Wire17 days ago

    Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress

    Acorda Therapeutics, Inc. (ACOR) today announced that it will debut an art gallery inspired by people with Parkinson’s (PwP) at the 5th World Parkinson Congress (WPC) in Kyoto, Japan. The six pieces of art, ranging from acrylic sculptures to oil paintings, are the centerpiece of Acorda’s Framing OFF Through Art initiative. OFF periods are the re-emergence of Parkinson’s symptoms, and affect approximately 40 percent of the one million people living with Parkinson’s in the U.S. This initiative builds on Acorda’s “Live Well.

  • Acorda (ACOR) Down 11.3% Since Last Earnings Report: Can It Rebound?
    Zacks19 days ago

    Acorda (ACOR) Down 11.3% Since Last Earnings Report: Can It Rebound?

    Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.